{
  "eval_id": "S46",
  "eval_file": "evals/single/S46.json",
  "timestamp": "2025-09-18T17:15:16.568112+00:00",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is indicated for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer who have received endocrine therapy and at least two prior systemic therapies, including a CDK4/6 inhibitor. Its main benefit in this setting is based on improved progression-free and overall survival versus chemotherapy, as per the label. Please send the SmPC or EMA summary by email so I can refer directly to the official details."
}